Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.

Author in
AI & Digital Bioeconomy & Society Startups & Deals NeuroTech Clinical Trials Biotech Manufacturing & Pharma 4.0 Tools & Methods HealthTech Aging & Longevity Contract Research Novel Therapeutics Marketing & E-commerce

Recent articles from Andrii

Synchron Becomes First to Achieve Native Thought-Control of Apple iPad Using Brain-Computer Interface

The New York-based medtech Synchron, a brain-computer interface (BCI) company backed by DARPA, Gates Frontier, and Bezos Expeditions, has become the first to publicly demonstrate native thought-based control of an Apple iPad. The demonstration, featuring a participant with ALS, marks …

No Clear Winner: 7-Year Brain Study Tests Rival Theories of Consciousness

A global team of researchers has carried out what may be the most ambitious attempt yet to test two of the most influential theories of consciousness: Integrated Information Theory (IIT) and Global Neuronal Workspace Theory (GNWT). Published today in Nature …

Study: Trust in Scientists Post-Pandemic Remains High, but Public Wants More Engagement

Led by researchers from Harvard University, ETH Zurich, and the University of Zurich, a recent international study sheds light on public perceptions of scientists and their role in society. This large-scale research, which engaged over 71,922 respondents …

Recursion and Faro Health Partner to Reimagine Clinical Trial Design with AI

Faro Health has partnered with Recursion to streamline clinical protocol design using Faro's AI-driven platform.

Eli Lilly Acquires Scorpion Therapeutics' Oncology Program for $2.5 Billion

Eli Lilly announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program for up to $2.5 billion, expanding its oncology pipeline with STX-478, a differentiated PI3Kα inhibitor currently in Phase 1/2 clinical trials.

Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases

Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory conditions. The partnership focuses on developing oral STAT6 small-molecule inhibitors and targeted protein degraders. STAT6 is a transcription factor …

Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation

Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including GENEVA OS, Green Button, and the Atropos Evidence Network. The partnership focuses on rapid cohort creation, advanced analytics, and generating …

Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing

Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety before clinical trials. The collaboration builds on a two-year validation study, where Quris-AI demonstrated higher accuracy in predicting drug-induced …

Calico's Small Molecule eIF2B Activator Falls Short in ALS Trial

Calico, the Alphabet-backed biotech focused on aging and longevity, has encountered a hurdle in its efforts to develop treatments for amyotrophic lateral sclerosis (ALS). Massachusetts General Hospital’s Healy ALS Platform trial found that fosigotifator, a candidate developed in collaboration …

21 Life Science Marketplaces to Try in 2024

(Last Update: December 2024, by adding Lab Spend, Labviva and more)

A life sciences marketplace is an online platform that operates with a "many-to-many" business logic, hosting multiple suppliers and buyers interacting via various e-commerce tools available as part of the website's functionality.